Wedbush Reiterates Outperform on Immunome, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Immunome (NASDAQ:IMNM) and maintained a price target of $33.
October 25, 2024 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Immunome and maintained a price target of $33, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a maintained price target of $33 by a reputable analyst suggests a positive outlook for Immunome. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100